Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.65 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.65 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.65 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.65 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.65 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.65 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.65 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.57 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | CNR2 | P34972 | 1/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6321234 | 0.83 | BCL2L1 (0.74) | BCL2L1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL31356465 | 0.83 | BCL2L1 (0.74) | BCL2L1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL7209477 | 0.83 | BCL2L1 (0.74) | BCL2L1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL93858 | 0.82 | BCL2L1 (1.00) | BCL2L1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL5355955 | 0.82 | BCL2L1 (0.71) | BCL2L1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL29438783 | 0.82 | BCL2L1 (1.00) | BCL2L1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL103529 | 0.80 | BCL2L1 (0.69) | BCL2L1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL6407980 | 0.80 | BCL2L1 (0.69) | BCL2L1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL826496 | 0.80 | BCL2L1 (0.69) | BCL2L1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL16599119 | 0.80 | BCL2L1 (0.69) | BCL2L1HDAC1HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | claimed |
| EP-1383748-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-01-28 | — | — | EP | claimed |
| WO-2002051983-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | WO | claimed |
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | disclosed |
| EP-1383748-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002051983-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | BCL2L1 444/4885HDAC1 284/4885HDAC3 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.